This is cutting edge stuff, as in drugs of this class being developed for diabetes pathologies indication. Dr. Ralph DeFronzo continues to be in the forefront of these developments and this fascinating interview is again highly educational about a subject matter that many on this site find of personal interest (I’m prediabetic!). There is a great deal of information about how to evaluate c-peptide tests and about the various phenotypes of people with elevated glucose.
Menin Inhibitors Discussion with Dr. Ralph DeFronzo (Biomea Fusion)
Meanwhile, here’s more about the drug class discussed above from the company presentation. I think it is obligatory viewing for anyone who wants to understand the mechanism of action of extremely cutting edge and novel approaches to diabetes management and the pathophysiology of glucose dysregulation.
Unlocking the Potential of Menin: ATTD-Asia 2024 (Biomea Fusion)
Biomea Fusion Presentation 2025.
Biomea Fusion: ATTD 2025 Breakfast Symposium
